Fluid biopsy for solid tumors: a patient's companion for lifelong characterization of their diseaseCurrent developments in adenovirus-based cancer gene therapyAdjuvant bisphosphonates in patients with breast cancer: does the potency matter?Next-generation prognostic assessment for diffuse large B-cell lymphomaWhat are the predictive factors in the risk and severity of chemotherapy-induced gastrointestinal toxicity?Present status and future perspectives of ALPPS (associating liver partition and portal vein ligation for staged hepatectomy)Mammalian target of rapamycin inhibitor-associated stomatitisIs carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia?A periodic table for cancerRole of hypoxia-inducible factors in breast cancer metastasisEnhancing cancer care in areas of limited resources: our next stepsFrontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinomaPET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literatureRecent advancements in multimodality treatment of gliomasNeoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancerBest use of experimental data in cancer informaticsAntibody, T-cell and dendritic cell immunotherapy for malignant brain tumorsHelicobacter pylori virulence and cancer pathogenesisA review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proofIbrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinaseHow to manage asparaginase hypersensitivity in acute lymphoblastic leukemiaIDH mutations in tumorigenesis and their potential role as novel therapeutic targets.Next-generation surveillance strategies for patients with lymphomaCurrent and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptorsWhat next for newly diagnosed glioblastoma?Practical management of classical myeloproliferative disorder patients: a clinician's guideBiomarkers identified to predict esophageal cancer susceptibility and aspirin found to lower cancer riskAMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agentCancer immunopreventionTranslating genomic profiling to gastrointestinal cancer treatment.Strategies to prevent peritoneal carcinomatosis arising from colorectal cancer.Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant.The importance of treating by histological subtype in advanced soft tissue sarcoma.Advances and controversies in the management of soft tissue sarcomas.Treatment of soft tissue sarcoma: a focus on earlier stages.Ipilimumab: from preclinical development to future clinical perspectives in melanoma.Focal therapy as primary treatment for localized prostate cancer: definition, needs and future.Cancer pain: a review of epidemiology, clinical quality and value impact.Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know?Outcomes and toxicities in patients treated with definitive focal therapy for primary prostate cancer: systematic review.
P1433
Q24623374-40289327-658C-411D-8468-B8ADC320E0D4Q24683229-4476B1CB-2205-403D-9E5A-4CCDBC1D6D10Q26781435-B8E646ED-D9AA-4BFD-A93C-8C58F4F6220CQ26796428-B01343F3-C58E-4B55-B3C4-32DF9BFAC485Q26798171-B6306C14-FC7F-42DB-BF5C-2A05AF9AEACDQ26799610-7EB82CB4-A655-4422-BFC5-7E44A891C96DQ26825301-506AD120-7A18-4382-8382-EC36CAB47ACAQ26849504-1094F32D-E843-4EB2-BED4-6E7A98248BADQ26858878-F812CF47-72DA-4196-839E-0F5AD23FAB61Q26860122-D6751411-7DB3-40A7-93F9-5E74E0E659FBQ26861387-5B5D0D1B-B8B9-4616-906E-8F96EC6546CBQ26863402-8922C33C-CC1F-4097-969D-47329617D9AAQ26992201-C573176C-05DD-4B2D-8FB5-A9BACB0BAB0AQ27001724-7B8D680A-123F-453B-8BC3-C76727FF04E6Q27003878-0CDE5A26-A80A-4F90-B001-5DEED22E4198Q27010374-60A5297D-92B9-4EAA-A9B5-468C285F4E73Q27011298-4EC0C0F6-0F45-41AC-8840-A1D8207E24DAQ27013699-45A760A9-6D18-4364-9848-A650174EF8B6Q27022812-143F9680-9ACC-4E45-B369-F24A51D918ADQ27026912-2DCCBDA5-6862-42F8-AB5F-826FF458716AQ27026952-A0155B50-65D5-44E8-973E-0A13714685E9Q27692015-FAF0BC77-F37E-44F3-B4DD-EAA2558DF6A0Q28084956-37911F4A-9E55-43C7-B9D4-C1CE76131639Q28086768-21630781-A07E-4FF1-BB38-4A172CABADDDQ28086839-F2C1495B-D938-496C-B723-330A4AA7DDCCQ28200207-51809799-52CF-47E1-B8F7-802FB29BA559Q28221370-0DE55CB3-46DA-4A5A-BAE0-030CD3B7EC07Q28286940-A9596729-1BBD-4474-8AB5-10313C8E2D5FQ28303393-43FFFD23-E293-4633-B7ED-952F67B29365Q30239109-0CD7245C-7F40-4E99-B22E-8F26708502E6Q30239825-CD5ED880-F34D-46A1-B0DE-8CC4ACB616D9Q30240140-F107A9EB-F7D8-4F36-9459-2CD945BA61F0Q30240223-96ED08F2-01DF-418B-9CB2-6953A2C87E46Q30240228-636F0105-7B8B-46AB-B498-7110111DE0BCQ30240235-EBC986F6-E18C-4387-A24B-19560EAD162DQ30240751-255D3338-E813-4BE2-846F-98E767F4A4EEQ30240753-6F67DCFB-1500-481A-80F8-5A24DF3C2502Q30240810-4BBD90F9-9520-41A7-A02C-49D10A1DC5A3Q30241331-FA7B268D-FAC5-4543-A48D-8F7DC91B7F9CQ30241856-3DE49094-B60E-4860-8868-D42B092492B6
P1433
description
begutachtete wissenschaftliche Zeitschrift
@de
peer-reviewed scientific journal
@en
periodiek van uitgeverij Future Medicine
@nl
revista científica
@es
rivista scientifica
@it
рецензований науковий журнал
@uk
वैज्ञानिक पत्रिका
@hi
name
Future Oncology
@de
Future Oncology
@en
Future Oncology
@es
Future Oncology
@it
Future Oncology
@nl
type
label
Future Oncology
@de
Future Oncology
@en
Future Oncology
@es
Future Oncology
@it
Future Oncology
@nl
prefLabel
Future Oncology
@de
Future Oncology
@en
Future Oncology
@es
Future Oncology
@it
Future Oncology
@nl
P243
P3181
P1055
P1058
P1156
4200151510
P1159
P123
P1250
P1277
P1476
Future Oncology
@en
P236
P243
P3181
P407
P571
2005-01-01T00:00:00Z